Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jan 08, 2018
-- Preliminary 2017 unaudited total revenues of approximately $195M, a 135% increase vs. 2016 --
-- Full-year 2018 net product revenue guidance of $260M to $295M --
-- Survival data from FIREFISH study in Type 1 SMA patients to be presented at upcoming SMA Congress --
Additional Formats
Jan 05, 2018
SOUTH PLAINFIELD, N.J. , Jan. 5, 2018 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 3, 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common stock to seven new employees.
Additional Formats
Jan 03, 2018
SOUTH PLAINFIELD, N.J. , Jan. 3, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 36 th Annual JP Morgan Healthcare Conference on Wednesday, January 10 th at 2:30 pm PT .
Additional Formats
Dec 15, 2017
SOUTH PLAINFIELD, N.J. , Dec. 15, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on December 11, 2017 it approved non-statutory stock options to purchase an aggregate of 10,000 shares of its common stock to two new employees.
Additional Formats
Nov 20, 2017
SOUTH PLAINFIELD, N.J. , Nov. 20, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on November 15, 2017 it approved non-statutory stock options to purchase an aggregate of 61,500 shares of its common stock to eight new employees.
Additional Formats
Nov 02, 2017
- Total third quarter revenue of $41.9M representing 82% growth over 3Q2016 -
- Increasing 2017 revenue guidance to $160-$185M -
Additional Formats
Oct 25, 2017
SOUTH PLAINFIELD, N.J. , Oct. 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of Drug Evaluation I of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) of the investigational
Additional Formats
Oct 24, 2017
SOUTH PLAINFIELD, N.J. , Oct. 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming Credit Suisse 26th Annual Healthcare Conference on Tuesday, November 7 at 1:35 pm MT .
Additional Formats
Oct 23, 2017
SOUTH PLAINFIELD, N.J. , Oct. 23, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on October 23, 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its common stock to eight new employees.
Additional Formats
Oct 19, 2017
SOUTH PLAINFIELD, N.J. , Oct. 19, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Thursday, November 2, 2017
Additional Formats